Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20178496 | 1.00 | BTK (0.47) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL1542181 | 1.00 | BTK (0.47) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL21423769 | 1.00 | BTK (0.47) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL1670964 | 1.00 | BTK (0.47) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL1542182 | 1.00 | BTK (0.47) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL25981800 | 1.00 | BTK (0.47) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL21622075 | 0.98 | GAA (0.49) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL21238714 | 0.96 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL22242735 | 0.96 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 | |
| SCHEMBL19578680 | 0.96 | BTK (0.51) | BTKGAAEPHX1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| WO-2025024822-A2 | PROCESSES FOR MAKING ARYL COMPOUNDS THAT MODULATE IKZF2 | Plexium, Inc. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025024823-A1 | SALTS AND SOLID FORMS OF COMPOUNDS THAT MODULATE IKZF2 | Plexium, Inc. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240398963-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | COVAL BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-12-05 | — | — | US | disclosed |
| US-20240262848-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | US | disclosed |
| US-20240246935-A1 | ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | Plexium, Inc. | 2024-07-25 | — | — | US | disclosed |
| EP-4367112-A1 | ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | Plexium, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11878968-B2 | Aryl compounds and pharmaceutical compositions that modulate IKZF2 | Plexium, Inc. (US) | 2024-01-23 | — | — | US | disclosed |
| CN-116836032-A | Preparation method of cis- (1S, 2R) -N-tert-butoxycarbonyl-1, 2-cyclohexanediamine | 泰州葛林美克医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-7192968-B2 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-02-22 | — | — | US | disclosed |
| US-20060004009-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| WO-2005087731-A1 | SULFUR COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11878968-B2 | Aryl compounds and pharmaceutical compositions that modulate IKZF2 | CRBN, IKZF1, IKZF3 | BTK 1855/4885GAA 2376/4885EPHX1 3683/4885 |
| US-20060004009-A1 | Ethylenediamine derivatives | F2, ECE1, MLLT1 | BTK 1597/4885GAA 4312/4885EPHX1 293/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | BTK 2629/4885GAA 4432/4885EPHX1 4180/4885 |
| US-20240246935-A1 | ARYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT MODULATE IKZF2 | CRBN, IKZF1, IKZF3 | BTK 1855/4885GAA 2376/4885EPHX1 3683/4885 |
| US-20240262848-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | KRAS, NRAS, HRAS | BTK 1022/4885GAA 1698/4885EPHX1 645/4885 |
| US-20070042968-A1 | Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease | PRSS1, PRSS3, HPN | BTK 1848/4885GAA 800/4885EPHX1 2134/4885 |
| US-20090227789-A1 | ETHYLENEDIAMINE DERIVATIVES | F2, ECE1, MLLT1 | BTK 1597/4885GAA 4312/4885EPHX1 293/4885 |
| US-20240398963-A1 | DRUG DELIVERY SYSTEM FOR LOCALLY DELIVERING THERAPEUTIC AGENTS AND USES THEREOF | TIE1, KDR, TEK | BTK 1349/4885GAA 364/4885EPHX1 2357/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | BTK 6/4885GAA 2316/4885EPHX1 1647/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | BTK 1123/4885GAA 4278/4885EPHX1 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.